SK287857B6 - Novel pyrrole derivatives as pharmaceutical agents - Google Patents
Novel pyrrole derivatives as pharmaceutical agents Download PDFInfo
- Publication number
- SK287857B6 SK287857B6 SK1416-2003A SK14162003A SK287857B6 SK 287857 B6 SK287857 B6 SK 287857B6 SK 14162003 A SK14162003 A SK 14162003A SK 287857 B6 SK287857 B6 SK 287857B6
- Authority
- SK
- Slovakia
- Prior art keywords
- pyridin
- dihydro
- pyrrolo
- pyrazol
- quinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29346401P | 2001-05-24 | 2001-05-24 | |
PCT/US2002/011884 WO2002094833A1 (en) | 2001-05-24 | 2002-05-13 | Novel pyrrole derivatives as pharmaceutical agents |
Publications (2)
Publication Number | Publication Date |
---|---|
SK14162003A3 SK14162003A3 (en) | 2004-11-03 |
SK287857B6 true SK287857B6 (sk) | 2012-01-04 |
Family
ID=23129192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1416-2003A SK287857B6 (sk) | 2001-05-24 | 2002-05-13 | Novel pyrrole derivatives as pharmaceutical agents |
Country Status (38)
Country | Link |
---|---|
US (1) | US7087626B2 (hu) |
EP (1) | EP1397364B1 (hu) |
JP (2) | JP4519407B2 (hu) |
KR (1) | KR100861630B1 (hu) |
CN (2) | CN1269820C (hu) |
AR (1) | AR036034A1 (hu) |
AT (1) | ATE368041T1 (hu) |
AU (1) | AU2002339268B2 (hu) |
BR (1) | BR0209939A (hu) |
CA (1) | CA2446820C (hu) |
CO (1) | CO5540282A2 (hu) |
CY (1) | CY1106871T1 (hu) |
CZ (1) | CZ303808B6 (hu) |
DE (1) | DE60221392T2 (hu) |
DK (1) | DK1397364T3 (hu) |
DZ (1) | DZ3506A1 (hu) |
EA (1) | EA007782B1 (hu) |
EC (1) | ECSP034859A (hu) |
EG (1) | EG25614A (hu) |
ES (1) | ES2289116T3 (hu) |
HK (1) | HK1064375A1 (hu) |
HR (1) | HRP20030961B1 (hu) |
HU (1) | HU228844B1 (hu) |
IL (2) | IL158512A0 (hu) |
MX (1) | MXPA03010630A (hu) |
MY (1) | MY134586A (hu) |
NO (1) | NO326701B1 (hu) |
NZ (1) | NZ528525A (hu) |
PE (1) | PE20030117A1 (hu) |
PL (1) | PL221339B1 (hu) |
PT (1) | PT1397364E (hu) |
SI (1) | SI1397364T1 (hu) |
SK (1) | SK287857B6 (hu) |
SV (1) | SV2003001054A (hu) |
TW (1) | TWI329644B (hu) |
UA (1) | UA76461C2 (hu) |
WO (1) | WO2002094833A1 (hu) |
ZA (1) | ZA200308546B (hu) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0209939A (pt) * | 2001-05-24 | 2004-03-30 | Lilly Co Eli | Composto ou seu sal, éster ou prodroga farmaceuticamente aceitável, formulação farmacêutica, uso do composto ou de seu sal, éster ou prodroga farmaceuticamente aceitável, e, método para tratar câncer |
ATE373000T1 (de) * | 2001-12-11 | 2007-09-15 | Smithkline Beecham Corp | Pyrazolopyridin-derivate als antiherpesmittel |
US7365066B2 (en) | 2002-09-17 | 2008-04-29 | Eli Lilly And Company | Pyrazolopyridine derivatives as pharmaceutical agents |
WO2004048383A1 (en) * | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
UA80571C2 (en) * | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
EP1578749A2 (en) * | 2002-11-22 | 2005-09-28 | Eli Lilly And Company | Pyrazoloazepine compounds as pharmaceutical agents |
WO2004050659A1 (en) * | 2002-11-27 | 2004-06-17 | Eli Lilly And Company | Novel compounds as pharmaceutical agents |
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
US7511065B2 (en) * | 2003-11-12 | 2009-03-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
EP1723146A1 (en) | 2004-03-01 | 2006-11-22 | Eli Lilly And Company | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
NZ561953A (en) | 2005-04-01 | 2011-11-25 | Insa Rouen | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents |
WO2007018818A1 (en) | 2005-07-22 | 2007-02-15 | Eli Lilly And Company | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
AU2006279794B2 (en) | 2005-08-12 | 2011-04-07 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
EP1973909A2 (en) * | 2005-12-22 | 2008-10-01 | Biogen Idec MA Inc. | Transforming growth factor modulators |
DE102005061840A1 (de) | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
CA2653217A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
US8642034B2 (en) | 2006-10-03 | 2014-02-04 | Genzyme Corporation | Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
ES2398677T3 (es) | 2007-12-12 | 2013-03-20 | E. I. Du Pont De Nemours And Company | Pirazoles bicíclicos fungicidas |
US8524707B2 (en) * | 2008-12-19 | 2013-09-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
US20100267731A1 (en) * | 2009-04-17 | 2010-10-21 | Summa Health Systems, LLC | Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring |
AR081810A1 (es) * | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
WO2011133520A1 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
EP2402340A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402338A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402339A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2401915A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402337A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
WO2012138945A1 (en) | 2011-04-08 | 2012-10-11 | Aestus Therapeutics, Inc. | Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta |
WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
WO2013062544A1 (en) | 2011-10-26 | 2013-05-02 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
CA2853806C (en) | 2011-11-02 | 2020-07-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法 |
EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
EA032679B1 (ru) | 2012-10-05 | 2019-07-31 | Кадмон Корпорейшн, Ллк | Человеческие анти-vegfr-2/kdr-антитела |
TWI443096B (zh) | 2012-12-18 | 2014-07-01 | Ind Tech Res Inst | 3-(5-(4-(3-氟丙基)哌嗪-1-基)苯並咪唑-2-基)-1-氮雜薁-2-酮之單水合晶型及其製備方法與藥學組成物 |
CA2900300A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4 |
DK3702443T3 (da) | 2013-03-14 | 2022-04-04 | Brigham & Womens Hospital Inc | Sammensætninger og fremgangsmåder til opformering og dyrkning af epiteliale stamceller |
US8975417B2 (en) * | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
SG11201606080SA (en) | 2014-02-03 | 2016-08-30 | Vitae Pharmaceuticals Inc | Dihydropyrrolopyridine inhibitors of ror-gamma |
EP3189134A1 (en) | 2014-09-03 | 2017-07-12 | The Brigham and Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
JO3336B1 (ar) | 2014-10-07 | 2019-03-13 | Lilly Co Eli | مركبات أمينو بيريديلوكسي بيرازول |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
ES2918924T3 (es) | 2015-04-01 | 2022-07-21 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
AU2017235461B2 (en) | 2016-03-15 | 2023-02-23 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
RU2737737C2 (ru) * | 2016-06-13 | 2020-12-02 | Джинфлит Терапьютикс (Шанхай) Инк. | АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI |
US11466003B2 (en) | 2016-07-29 | 2022-10-11 | Shanghai Yingli Pharmaceutical Co., Ltd | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof |
MX2019007890A (es) | 2016-12-30 | 2020-01-20 | Frequency Therapeutics Inc | Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte. |
US11045472B2 (en) | 2017-05-05 | 2021-06-29 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
WO2019023207A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF RORƳ |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
KR20200067170A (ko) | 2017-10-05 | 2020-06-11 | 풀크럼 쎄러퓨틱스, 인코포레이티드 | FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제 |
SG11202003283TA (en) | 2017-10-11 | 2020-05-28 | Hoffmann La Roche | Bicyclic compounds for use as rip1 kinase inhibitors |
JP2021035911A (ja) * | 2017-11-15 | 2021-03-04 | 大日本住友製薬株式会社 | 縮環ピラゾール誘導体及びその医薬用途 |
JP7028977B2 (ja) * | 2017-12-13 | 2022-03-02 | ジェンフリート セラピューティクス(シャンハイ)インコーポレイテッド | TGF-βRI阻害剤の結晶形、塩形態及びその製造方法 |
CN110066277B (zh) | 2018-01-24 | 2021-07-23 | 上海璎黎药业有限公司 | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 |
CN110066276B (zh) | 2018-01-24 | 2020-09-18 | 上海璎黎药业有限公司 | 芳香杂环化合物、其中间体、制备方法、药物组合物和应用 |
JP2021518413A (ja) | 2018-03-20 | 2021-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
WO2020019108A1 (en) | 2018-07-23 | 2020-01-30 | Guangzhou Othrotx Co., Ltd. | Bisphosphonate drug conjugates |
AU2019321641A1 (en) | 2018-08-17 | 2021-04-15 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating Jag-1 |
US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
KR102126576B1 (ko) | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
WO2020088526A1 (zh) * | 2018-10-31 | 2020-05-07 | 南京明德新药研发有限公司 | 作为TGF-βR1激酶抑制剂的双环吡唑类化合物 |
JP7466128B2 (ja) * | 2018-11-22 | 2024-04-12 | フンダシオ インスティテュート デ レセルカ ビオメディカ(アイアールビー バルセロナ) | TGFβ阻害剤およびプロドラッグ |
US12102626B2 (en) | 2018-12-27 | 2024-10-01 | Nexys Therapeutics, Inc. | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer |
CA3124700A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
US20220098171A1 (en) | 2019-01-24 | 2022-03-31 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR |
WO2020160151A1 (en) * | 2019-01-31 | 2020-08-06 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
WO2020248908A1 (zh) * | 2019-06-10 | 2020-12-17 | 中国科学院广州生物医药与健康研究院 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
AU2021205893A1 (en) | 2020-01-08 | 2022-06-23 | Synthis Therapeutics, Inc. | ALK5 inhibitor conjugates and uses thereof |
CN114867723B (zh) * | 2020-07-23 | 2023-05-30 | 江苏奥赛康药业有限公司 | 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物 |
WO2022063050A1 (zh) | 2020-09-28 | 2022-03-31 | 四川科伦博泰生物医药股份有限公司 | 吡唑类化合物及其制备方法和用途 |
CN114437082A (zh) * | 2020-11-06 | 2022-05-06 | 江苏先声药业有限公司 | 喹啉类化合物 |
CN115703750B (zh) * | 2021-08-17 | 2024-07-02 | 黑龙江华瑞生物科技有限公司 | 一种1-氨基-4-甲基哌嗪的提取纯化方法 |
CN114249742B (zh) * | 2021-11-22 | 2022-11-01 | 郑州大学 | 一种光气探针、荧光书写检测笔及其在光气检测中的应用 |
CN115969801B (zh) * | 2023-03-21 | 2023-08-25 | 劲方医药科技(上海)有限公司 | 用于癌症的药物组合物及其制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
JPH07507796A (ja) * | 1992-06-17 | 1995-08-31 | ファルマシア・アンド・アップジョン・カンパニー | 抗−アテローム性動脈硬化剤および抗−高コレステロール血症剤として有用なピリジノ−,ピロリジノ−,およびアゼピノ−置換オキシム類 |
GB9303993D0 (en) * | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
US5565460A (en) * | 1993-07-27 | 1996-10-15 | Kyowa Hakko Koygo Co., Ltd. | Therapeutic purine agents for parkinson's disease |
US5358947A (en) | 1993-09-13 | 1994-10-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones |
AUPN419395A0 (en) * | 1995-07-17 | 1995-08-10 | Treescope Development Co. Pty. Ltd. | Plant protector |
FR2746306B1 (fr) * | 1996-03-22 | 1998-04-30 | Oreal | Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture |
EP1000055A1 (en) | 1997-05-22 | 2000-05-17 | G.D. Searle & Co. | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
FR2772379B1 (fr) | 1997-12-16 | 2000-02-11 | Oreal | Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procede de teinture; nouveaux pyrazolo-azoles |
GB9809869D0 (en) | 1998-05-09 | 1998-07-08 | Medical Res Council | Inhibition of protein kinases |
EP1156045A4 (en) * | 1999-01-28 | 2002-04-17 | Nippon Shinyaku Co Ltd | AMID DERIVATIVES AND DRUG COMPOSITIONS |
ATE231143T1 (de) | 1999-04-09 | 2003-02-15 | Smithkline Beecham Corp | Triarylimidazole |
PT1206474E (pt) * | 1999-08-27 | 2004-10-29 | Abbott Lab | Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2 |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
EP1326619A2 (en) * | 2000-10-11 | 2003-07-16 | Merck & Co., Inc. | Pyrrolidine modulators of ccr5 chemokine receptor activity |
US20040087623A1 (en) | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
BR0209939A (pt) * | 2001-05-24 | 2004-03-30 | Lilly Co Eli | Composto ou seu sal, éster ou prodroga farmaceuticamente aceitável, formulação farmacêutica, uso do composto ou de seu sal, éster ou prodroga farmaceuticamente aceitável, e, método para tratar câncer |
CN1795296B (zh) * | 2003-05-28 | 2010-09-08 | M&J纤维技术有限公司 | 用于对纤维施以空气的方法及纤维分布器 |
JP4882198B2 (ja) | 2003-09-25 | 2012-02-22 | 日産自動車株式会社 | 燃料電池システム |
-
2002
- 2002-05-13 BR BR0209939-0A patent/BR0209939A/pt not_active Application Discontinuation
- 2002-05-13 WO PCT/US2002/011884 patent/WO2002094833A1/en active IP Right Grant
- 2002-05-13 CZ CZ20033128A patent/CZ303808B6/cs not_active IP Right Cessation
- 2002-05-13 MX MXPA03010630A patent/MXPA03010630A/es active IP Right Grant
- 2002-05-13 CN CNB028105087A patent/CN1269820C/zh not_active Expired - Fee Related
- 2002-05-13 PT PT02744115T patent/PT1397364E/pt unknown
- 2002-05-13 SK SK1416-2003A patent/SK287857B6/sk not_active IP Right Cessation
- 2002-05-13 KR KR1020037015226A patent/KR100861630B1/ko not_active IP Right Cessation
- 2002-05-13 PL PL367199A patent/PL221339B1/pl unknown
- 2002-05-13 CA CA2446820A patent/CA2446820C/en not_active Expired - Fee Related
- 2002-05-13 IL IL15851202A patent/IL158512A0/xx unknown
- 2002-05-13 HU HU0400451A patent/HU228844B1/hu not_active IP Right Cessation
- 2002-05-13 JP JP2002591506A patent/JP4519407B2/ja not_active Expired - Fee Related
- 2002-05-13 ES ES02744115T patent/ES2289116T3/es not_active Expired - Lifetime
- 2002-05-13 DK DK02744115T patent/DK1397364T3/da active
- 2002-05-13 US US10/477,111 patent/US7087626B2/en not_active Expired - Fee Related
- 2002-05-13 NZ NZ528525A patent/NZ528525A/en not_active IP Right Cessation
- 2002-05-13 AT AT02744115T patent/ATE368041T1/de active
- 2002-05-13 EA EA200301289A patent/EA007782B1/ru not_active IP Right Cessation
- 2002-05-13 AU AU2002339268A patent/AU2002339268B2/en not_active Ceased
- 2002-05-13 DE DE60221392T patent/DE60221392T2/de not_active Expired - Lifetime
- 2002-05-13 SI SI200230626T patent/SI1397364T1/sl unknown
- 2002-05-13 CN CNA2006100946748A patent/CN1951939A/zh active Pending
- 2002-05-13 EP EP02744115A patent/EP1397364B1/en not_active Expired - Lifetime
- 2002-05-13 UA UA20031110606A patent/UA76461C2/uk unknown
- 2002-05-15 DZ DZ023506A patent/DZ3506A1/fr active
- 2002-05-22 EG EG2002050542A patent/EG25614A/xx active
- 2002-05-24 PE PE2002000435A patent/PE20030117A1/es not_active Application Discontinuation
- 2002-05-24 MY MYPI20021941A patent/MY134586A/en unknown
- 2002-05-24 TW TW091111082A patent/TWI329644B/zh not_active IP Right Cessation
- 2002-05-24 SV SV2002001054A patent/SV2003001054A/es unknown
- 2002-05-27 AR ARP020101974A patent/AR036034A1/es not_active Application Discontinuation
-
2003
- 2003-10-20 IL IL158512A patent/IL158512A/en not_active IP Right Cessation
- 2003-10-31 ZA ZA2003/08546A patent/ZA200308546B/en unknown
- 2003-11-18 CO CO03101666A patent/CO5540282A2/es active IP Right Grant
- 2003-11-21 EC EC2003004859A patent/ECSP034859A/es unknown
- 2003-11-21 HR HR20030961A patent/HRP20030961B1/xx not_active IP Right Cessation
- 2003-11-21 NO NO20035193A patent/NO326701B1/no not_active IP Right Cessation
-
2004
- 2004-09-15 HK HK04107054A patent/HK1064375A1/xx not_active IP Right Cessation
-
2007
- 2007-09-17 CY CY20071101193T patent/CY1106871T1/el unknown
-
2009
- 2009-04-27 JP JP2009108167A patent/JP2009197016A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7087626B2 (en) | Pyrrole derivatives as pharmaceutical agents | |
US7365066B2 (en) | Pyrazolopyridine derivatives as pharmaceutical agents | |
AU2002339268A1 (en) | Novel pyrrole derivatives as pharmaceutical agents | |
EP1740591B1 (en) | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | |
US20070208053A1 (en) | Fused heterobicyclic kinase inhibitors | |
US20050208582A1 (en) | Pyrazole compounds and pharmaceutical compositions comprising the compound | |
JP6549311B2 (ja) | インドール誘導体、その調製方法および医薬におけるその使用 | |
KR20080059184A (ko) | 단백질 키나제 억제제로서의티에노[2,3-b]피리딘-5-카르보니트릴 | |
US7381725B2 (en) | Pyridazine derivatives as ligands for GABA receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20180513 |